DAK calls for cold storage facilities for potential COVID vaccine

Moderna's Chief Medical Officer Dr. Tal Zaks

"We remain committed to and focused on doing our part to help end the COVID-19 pandemic".

While the data is not peer-reviewed yet and there is still a lot more worked to be done, this announcement together with the ones from last week has been welcomed with excitement.

BioNTech and co-developer Pfizer, last week, said their vaccine's preliminary analysis showed that it could prevent more than 90 per cent of people from getting COVID-19.

The trials were created to measure whether the vaccines stop people from getting sick rather than whether they prevent transmission, which remains to be tested. The other half got a placebo.

"We are going to have a vaccine that can stop Covid-19", Moderna President Stephen Hoge said in a telephone interview.

Boasting of the trial results by the US-based biotechnology company, Trump said that "these great discoveries" happened on his watch.

"The vaccine is really the light at the end of the tunnel", Dr. Anthony Fauci, the top USA infectious diseases expert said.

Speaking on BBC "Breakfast", Hancock said Britain will be "ready from the first of December", but that more likely it will begin "rolling out before Christmas". Some volunteers reported mild or moderate symptoms, such as fatigue or headache. 11 people had severe Covid-19 but none of these were among those immunized. Eleven of the 95 people infected with the virus were diagnosed with severe cases.

There were 11 people who fell severely ill, all of whom were in the placebo group.

It will seek emergency use authorisation from the US Food and Drug Administration once it has more safety data, expected later this month.

However, UK does not have any prior order placed for Moderna's COVID-19 vaccines as yet.

Last week the Commission reached a deal with Pfizer and BioNTech on the supply of their potential Covid-19 vaccine hours after the companies announced their positive results, European Union officials said, adding that the timing was a coincidence. If all works, then our immune cells can recognize the proteins whenever. There are a dozen coronavirus vaccine candidates in late-stage trials globally, and they employ a variety of approaches. While RNA is a technology that has been considered promising for awhile, it's never been approved for use in humans.

Crucially, Moderna also announced that its vaccine can remain stable at standard refrigerator temperatures of 2 degrees Celsius to 8 degrees Celsius (36 degrees Fahrenheit to 46 degrees Fahrenheit) for 30 days.

Pfizer vaccine requires ultra-cold storage ( -75 °C/ -103 °F), but it can be kept in the fridge for five days. Officials said advisory groups will figure out if which vaccines work best for specific populations, or if one vaccine is optimal for logistical reasons - for instance, rural areas might find Moderna's refrigeration specifications more feasible.

"This news from Moderna is tremendously exciting and considerably boosts optimism that we will have a choice of good vaccines in the next few months", said Peter Openshaw, professor of experimental medicine at Imperial College London.

USA biotech firm Moderna on Monday announced its experimental vaccine against Covid-19 was nearly 95 percent effective, marking a second major breakthrough in the quest to end the pandemic.

This is a developing story and will be updated.



Other news